• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Kymab

edit

Kymab Limited discovers, develops, and commercializes human therapeutic monoclonal antibodies for the treatment of human diseases using its proprietary Kymouse platform. Its platform captures the diversity of the B lymphocyte component of the human immune system and generates human antibody-based biopharmaceuticals directed against clinically precedented drug targets and drugs against novel targets. The company was incorporated in 2009 and is based in Cambridge, the United Kingdom.

Milestones

edit

• 
  Kymab added Paulette Alexander as Office Manager.
  Posted 10/31/10 at 6:54pm
• 
  Kymab added Andrew P Sandham as Chairman & CEO.
  Posted 10/31/10 at 6:54pm
• 
  Kymab received $30.4M in Series A funding. (7/12/10)
  Posted 10/31/10 at 6:54pm via kymab.com

Videos

Screenshots

edit

Sources

1. Kymab and Wellcome Trust sign £20 million financing to build a UK biopharmaceutical company based on human monoclonal antibody technology from The Sanger Institute (kymab.com) [edit]